Relationship between Susceptibility to Daptomycin In Vitro and Activity In Vivo in a Rabbit Model of Aortic Valve Endocarditis
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Daptomycin is approved for treatment of Staphylococcus aureus bacteremia and right-sided endocarditis. Increases in daptomycin MICs have been associated with failure. A rabbit model of aortic valve endocarditis was used to determine whether MIC correlates with activity in vivo and whether a higher daptomycin dose can improve efficacy. Two related clinical S. aureus strains, one with a daptomycin MIC of 0.5 μg/ml and the other with a MIC of 2 μg/ml, were used to establish aortic valve endocarditis in rabbits. Daptomycin was administered once a day for 4 days at 12 mg/kg of body weight or 18 mg/kg to simulate doses in humans of 6 mg/kg and 10 mg/kg, respectively. Endocardial vegetations, spleens, and kidneys were harvested and quantitatively cultured. The strain with a MIC of 2 μg/ml had a survival advantage over the strain with a MIC of 0.5 μg/ml with >100 times more organisms of the former in endocardial vegetations at the 12-mg/kg dose in a dual-infection model. Both the 12-mg/kg dose and the 18-mg/kg dose completely eradicated the strain with a MIC of 0.5 from vegetations, spleens, and kidneys. The 12-mg/kg dose was ineffective against the strain with a MIC of 2 in vegetations; the 18-mg/kg dose produced a reduction of 3 log 10 units in CFU in vegetations compared to the controls, although in no rabbit were organisms completely eliminated. Increasing the dose of daptomycin may improve its efficacy for infections caused by strains with reduced daptomycin susceptibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Self-citationMcDougal, L. K., Steward, C. D., Killgore, G. E., Chaitram, J. M., McAllister, S. K., & Tenover, F. C. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.11.5113-5120.2003 · Cited by 1,399
Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus
Friedman, L., Alder, J. D., & Silverman, J. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00039-06 · Cited by 454
Self-citationIn Vivo Pharmacodynamic Activity of Daptomycin
Safdar, N., Andes, D., & Craig, W. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.63-68.2004 · Cited by 370
Dvorchik, B. H., Brazier, D., DeBruin, M. F., & Arbeit, R. D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1318-1323.2003 · Cited by 358
Benvenuto, M., Benziger, D. P., Yankelev, S., & Vigliani, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00247-06 · Cited by 319
Pharmacodynamics of Daptomycin in a Murine Thigh Model of Staphylococcus aureus Infection
Louie, A., Kaw, P., Liu, W., Jumbe, N., Miller, M. H., & Drusano, G. L. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.845-851.2001 · Cited by 172 · cited 2×
“Daptomycin exhibits concentration-dependent killing, and its efficacy has been correlated with two pharmacokinetic/pharmacodynamic parameters, AUC/MIC and maximum concentration of drug in serum/MIC, in various in vitro and in vivo infection models (8, 11).”
BackgroundJulian, K., Kosowska-Shick, K., Whitener, C., Roos, M., Labischinski, H., Rubio, A., Parent, L., Ednie, L., Koeth, L., Bogdanovich, T., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00559-07 · Cited by 119
Shopsin, B., Gomez, M., Waddington, M., Riehman, M., & Kreiswirth, B. N. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.9.3453-3456.2000 · Cited by 114
Rose, W. E., Leonard, S. N., & Rybak, M. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00102-08 · Cited by 90
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Bayer, A. S., Schneider, T., & Sahl, H. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06819.x · Cited by 311
A Current Perspective on Daptomycin for the Clinical Microbiologist
Humphries, R. M., Pollett, S., & Sakoulas, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-13 · Cited by 240
Kullar, R., Davis, S. L., Levine, D. P., Zhao, J. J., Crank, C. W., Segreti, J., Sakoulas, G., Cosgrove, S. E., & Rybak, M. J. (2011) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.6.527 · Cited by 136
Safety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin Therapy
Moise, P. A., Hershberger, E., Amodio-Groton, M. I., & Lamp, K. C. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m085 · Cited by 136
Yang, S.-J., Xiong, Y. Q., Boyle-Vavra, S., Daum, R., Jones, T., & Bayer, A. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00487-10 · Cited by 130
Moise, P. A., North, D. S., Steenbergen, J. N., & Sakoulas, G. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70200-2 · Cited by 130
Self-citationMunita, J. M., Panesso, D., Diaz, L., Tran, T. T., Reyes, J., Wanger, A., Murray, B. E., & Arias, C. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00509-12 · Cited by 118
Kullar, R., Casapao, A. M., Davis, S. L., Levine, D. P., Zhao, J. J., Crank, C. W., Segreti, J., Sakoulas, G., Cosgrove, S. E., & Rybak, M. J. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt294 · Cited by 99
Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges
Kern, W. V. (2010) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32833bcc8a · Cited by 102
Daptomycin: The role of high-dose and combination therapy for Gram-positive infections
Gould, I. M., Miró, J. M., & Rybak, M. J. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.05.005 · Cited by 93
Xiong, Y. Q., Abdelhady, W., Deslandes, A., Rey, A., Fraisse, L., Kristensen, H., Yeaman, M. R., & Bayer, A. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00453-11 · Cited by 74
Boyle‐Vavra, S., Jones, M. B., Gourley, B. L., Holmes, M. H., Ruf, R. A. S., Balsam, A. R., Boulware, D. R., Kline, S., Jawahir, S., DeVries, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01593-10 · Cited by 68
García-de-la-Mària, C., Gasch, O., García‐González, J., Soy, D., Shaw, E., Ambrosioni, J., Almela, M., Pericàs, J. M., Téllez, A., Falces, C., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02633-17 · Cited by 55
Vancomycin-Resistant Enterococcal Bacteremia Pharmacotherapy
Patel, R., & Gallagher, J. C. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014556879 · Cited by 58
Yang, S., Xiong, Y. Q., Yeaman, M. R., Bayles, K. W., Abdelhady, W., & Bayer, A. S. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00412-13 · Cited by 50
Lai, C.-C., Sheng, W., Wang, J., Cheng, A., Chuang, Y., Chen, Y., & Chang, S. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-66 · Cited by 39
Timbrook, T. T., Caffrey, A. R., Luther, M. K., Lopes, V., & LaPlante, K. L. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2070 · Cited by 39
High-Dose Daptomycin and Clinical Applications
Jones, T. W., Jun, A. H., Michal, J. L., & Olney, W. J. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028021991943 · Cited by 42
Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data
Senneville, É., Caillon, J., Calvet, B., & Jehl, F. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.11.005 · Cited by 39
Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis
Durante‐Mangoni, E., Andini, R., Parrella, A., Mattucci, I., Cavezza, G., Senese, A., Trojaniello, C., Caprioli, R., Diana, M. V., & Utili, R. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.04.022 · Cited by 35
Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci
Cervera, C., Castañeda, X., Pericàs, J. M., del Río, A., de la Mària, C. G., Mestres, C. A., Falces, C., Marco, F., Moreno, A., & Miró, J. M. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.038 · Cited by 36
Chaves, R. L., Chakraborty, A., Benziger, D. P., & Tannenbaum, S. J. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt342 · Cited by 35
Jean, S., Liu, I.-M., Hsieh, P.-C., Kuo, D.-H., Liu, Y.-L., & Hsueh, P. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106763 · Cited by 34
Riser, M. S., Bland, C. M., Rudisill, C. N., & Bookstaver, P. B. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1p307 · Cited by 31
High-Dose Daptomycin Therapy for Staphylococcal Endocarditis and When to Apply It
Smith, J. R., Claeys, K. C., Barber, K. E., & Rybak, M. J. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0429-6 · Cited by 31
Mishra, N. N., Lew, C., Abdelhady, W., Lapitan, C. K., Proctor, R. A., Rose, W. E., & Bayer, A. S. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01649-21 · Cited by 26
Xiong, Y. Q., Abdelhady, W., Bayer, A. S., Chen, L., Kreiswirth, B. N., & Yang, S. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00922-12 · Cited by 21
Animal models of organic heart valve disease
Roosens, B., Bala, G., Droogmans, S., Camp, G. V., Breyne, J., & Cosyns, B. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.065 · Cited by 24
Chambers, H. F. “., Basuino, L., Hamilton, S. M., Choo, E. J., & Moise, P. A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00589-16 · Cited by 20
Self-citationOptimizing therapy for vancomycin-resistant enterococcal bacteremia in children
Tamma, P. D., & Hsu, A. J. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000115 · Cited by 18
Human-Simulated Antimicrobial Regimens in Animal Models: Transparency and Validation Are Imperative
Gill, C. M., Asempa, T. E., & Nicolau, D. P. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00594-20 · Cited by 16
Karau, M. J., Schmidt-Malan, S. M., Mandrekar, J. N., Lehoux, D. E., Schuch, R., Cassino, C., & Patel, R. (2022) · Journal of Bone and Joint Infection · doi:10.5194/jbji-7-169-2022 · Cited by 15
Xiong, Y. Q., Abdelhady, W., Tang, C. ‘., & Bayer, A. S. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw249 · Cited by 12
Vidaillac, C., Steed, M. E., & Rybak, M. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01291-10 · Cited by 11
Abdelhady, W., Bayer, A. S., Gonzales, R., Li, L., & Xiong, Y. Q. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01877-16 · Cited by 10
Therapeutic drug monitoring of antibiotics in critically ill patients
Horn, D., Klaas, C., Fobker, M., Köck, R., & Lanckohr, C. (2019) · Handbook of analytical separations · doi:10.1016/b978-0-444-64066-6.00008-3 · Cited by 9
Persha, H., Thacker, S. A., Hornback, K. M., Alvira-Arill, G. R., Lueking, R. R., & Morrisette, T. (2024) · Antibiotics · doi:10.3390/antibiotics13090833 · Cited by 6
Therapeutic Drug Monitoring: More Than Avoiding Toxicity
Stojanova, J., & Luque, S. (2017) · Springer eBooks · doi:10.1007/978-981-10-5336-8_9 · Cited by 3
Morales‐Cartagena, A. (2015) · World Journal of Clinical Infectious Diseases · doi:10.5495/wjcid.v5.i2.14 · Cited by 4
Retos en el tratamiento antimicrobiano de la endocarditis infecciosa. Papel de la daptomicina
Almirante, B., & Miró, J. M. (2012) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(12)70068-x · Cited by 2
Combined Antimicrobial Therapy for Infective Endocarditis
Gomez-Villegas, S. I., Miller, W. R., & Arias, C. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65839-6_16
Metadata
- Authors
- Chambers, H. F., Basuino, L., Diep, B. A., Steenbergen, J., Zhang, S., Tattevin, P., & Alder, J.
- Affiliations
- San Francisco General Hospital (US)
- Cubist Pharmaceuticals (United States) (US)
- Hôpital Pontchaillou (FR)
- Bayer HealthCare, Monteville, New Jersey
- Corresponding author
- Chambers, H. F.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-04
- Volume
- 53
- Issue
- 4
- Pages
- 1463-1467
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2663086
- OpenAlex
- W2089885764
- Semantic Scholar
- 0fb502dbfa6895e084cc6869a783711b37201300
- Cited by
- 42
- References
- 12
- Citations by year
- 2024: 2 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 3 · 2014: 3 · 2013: 6 · 2012: 5
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- daptomycin, Staphylococcus aureus, aortic valve endocarditis, antimicrobial susceptibility, minimum inhibitory concentration, dose-response relationship, endocardial vegetation, rabbit model, bacteremia, co-infection
- MeSH terms
- Animals, Anti-Bacterial Agents, Aortic Valve, Disease Models, Animal, Dose-Response Relationship, Drug, Endocarditis, Bacterial, Heart Valve Diseases, Microbial Sensitivity Tests, Rabbits, Staphylococcal Infections, Staphylococcus aureus, Daptomycin, Area Under Curve
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.